NASDAQ:KROS Keros Therapeutics (KROS) Stock Price, News & Analysis $10.19 -0.60 (-5.56%) Closing price 04:00 PM EasternExtended Trading$10.18 -0.01 (-0.15%) As of 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Keros Therapeutics Stock (NASDAQ:KROS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Keros Therapeutics alerts:Sign Up Key Stats Today's Range$9.71▼$10.3250-Day Range$10.15▼$12.0252-Week Range$9.71▼$72.37Volume1.99 million shsAverage Volume1.31 million shsMarket Capitalization$413.33 millionP/E RatioN/ADividend YieldN/APrice Target$42.33Consensus RatingModerate Buy Company OverviewKeros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment of obesity and neuromuscular diseases. In addition, the company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize KER-050 and licensed products containing KER-050. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.Read More… Remove Ads Keros Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks73rd Percentile Overall ScoreKROS MarketRank™: Keros Therapeutics scored higher than 73% of companies evaluated by MarketBeat, and ranked 277th out of 935 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingKeros Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on 8 buy ratings, 6 hold ratings, and no sell ratings.Amount of Analyst CoverageKeros Therapeutics has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Keros Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Keros Therapeutics are expected to decrease in the coming year, from ($4.74) to ($4.87) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Keros Therapeutics is -1.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Keros Therapeutics is -1.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioKeros Therapeutics has a P/B Ratio of 0.90. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Keros Therapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted12.87% of the float of Keros Therapeutics has been sold short.Short Interest Ratio / Days to CoverKeros Therapeutics has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Keros Therapeutics has recently decreased by 3.83%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldKeros Therapeutics does not currently pay a dividend.Dividend GrowthKeros Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted12.87% of the float of Keros Therapeutics has been sold short.Short Interest Ratio / Days to CoverKeros Therapeutics has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Keros Therapeutics has recently decreased by 3.83%, indicating that investor sentiment is improving. News and Social Media2.9 / 5News Sentiment1.14 News SentimentKeros Therapeutics has a news sentiment score of 1.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.82 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Keros Therapeutics this week, compared to 4 articles on an average week. Company Ownership3.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Keros Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders22.90% of the stock of Keros Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions71.56% of the stock of Keros Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Keros Therapeutics' insider trading history. Receive KROS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Keros Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address KROS Stock News HeadlinesKeros Therapeutics Announces Initial Topline Results from the Phase 1 Clinical Trial of KER-065 in Healthy VolunteersMarch 31 at 6:00 AM | globenewswire.comBrokerages Set Keros Therapeutics, Inc. (NASDAQ:KROS) PT at $42.33March 31 at 1:33 AM | americanbankingnews.comYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your free gift, and see how Trump's victory could spark major gains for gold.March 31, 2025 | American Alternative (Ad)Keros Therapeutics: Losing Its Lead Drug Is Bad MedicineMarch 13, 2025 | seekingalpha.comBank of America Securities Remains a Buy on Keros Therapeutics (KROS)March 2, 2025 | markets.businessinsider.comKeros Therapeutics Announces Participation at Upcoming Healthcare ConferencesFebruary 28, 2025 | globenewswire.comKeros Therapeutics, Inc.: Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial ResultsFebruary 28, 2025 | finanznachrichten.deWells Fargo Sticks to Their Buy Rating for Keros Therapeutics (KROS)February 27, 2025 | markets.businessinsider.comSee More Headlines KROS Stock Analysis - Frequently Asked Questions How have KROS shares performed this year? Keros Therapeutics' stock was trading at $15.83 at the beginning of the year. Since then, KROS stock has decreased by 36.8% and is now trading at $10.0070. View the best growth stocks for 2025 here. How were Keros Therapeutics' earnings last quarter? Keros Therapeutics, Inc. (NASDAQ:KROS) posted its quarterly earnings data on Wednesday, February, 26th. The company reported ($1.14) EPS for the quarter, topping the consensus estimate of ($1.36) by $0.22. The company had revenue of $3.04 million for the quarter, compared to analysts' expectations of $37.32 million. Keros Therapeutics had a negative trailing twelve-month return on equity of 41.74% and a negative net margin of 27,890.94%. When did Keros Therapeutics IPO? Keros Therapeutics (KROS) raised $75 million in an initial public offering on Wednesday, April 8th 2020. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Jefferies, SVB Leerink and Piper Sandler served as the underwriters for the IPO and H.C. Wainwright & Co. was co-manager. Who are Keros Therapeutics' major shareholders? Top institutional investors of Keros Therapeutics include Vanguard Group Inc. (4.83%), Braidwell LP (4.68%), Darwin Global Management Ltd. (4.16%) and Alkeon Capital Management LLC (2.72%). Insiders that own company stock include Jennifer Lachey, Christopher Rovaldi and Keith Regnante. View institutional ownership trends. How do I buy shares of Keros Therapeutics? Shares of KROS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Keros Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Keros Therapeutics investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Netflix (NFLX), Meta Platforms (META) and Home Depot (HD). Company Calendar Last Earnings2/26/2025Today3/31/2025Next Earnings (Estimated)5/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:KROS CIK1664710 Webwww.kerostx.com Phone617-314-6297FaxN/AEmployees100Year FoundedN/APrice Target and Rating Average Stock Price Target$42.33 High Stock Price Target$102.00 Low Stock Price Target$15.00 Potential Upside/Downside+318.8%Consensus RatingModerate Buy Rating Score (0-4)2.57 Research Coverage14 Analysts Profitability EPS (Most Recent Fiscal Year)($5.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-152,990,000.00 Net Margins-27,890.94% Pretax Margin-27,890.94% Return on Equity-41.74% Return on Assets-38.42% Debt Debt-to-Equity RatioN/A Current Ratio19.03 Quick Ratio19.03 Sales & Book Value Annual Sales$3.55 million Price / Sales115.50 Cash FlowN/A Price / Cash FlowN/A Book Value$11.09 per share Price / Book0.91Miscellaneous Outstanding Shares40,562,000Free Float31,231,000Market Cap$410.04 million OptionableOptionable Beta1.39 (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:KROS) was last updated on 3/31/2025 by MarketBeat.com Staff From Our PartnersYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredTrump’s Great Society Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredAI Boom Takes a Shocking Turn…AI is Creating Fortunes… (but not where you think!) Bryce Paul and the team at Crypto101 just released a br...Crypto 101 Media | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Keros Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Keros Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.